teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 8 Projects Releases Packages Wiki Activity Actions 1

entity-batch: update 1 entities
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details

Browse source 
- Applied 1 entity operations from queue
- Files: domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents 2026-03-30 09:35:29 +00:00
parent e64c062373
commit 95ef6b229f
1 changed files with 15 additions and 0 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

15
domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
View file

@ -38,6 +38,21 @@ SELECT trial prespecified analysis (N=17,604) published in The Lancet November 2
ESC 2024 mediation analysis (Colhoun/Lincoff) found hsCRP (inflammation marker) mediated 42.1% of CV benefit while body weight mediated only 19.5%. Joint mediation of all measured metabolic factors was 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% of benefit unexplained by adiposity or standard metabolic parameters. The convergence between this analysis (68.6% unexplained) and the Lancet prespecified analysis (67% weight-independent) from independent methodologies strengthens the anti-inflammatory mechanism hypothesis. ESC 2024 mediation analysis (Colhoun/Lincoff) found hsCRP (inflammation marker) mediated 42.1% of CV benefit while body weight mediated only 19.5%. Joint mediation of all measured metabolic factors was 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% of benefit unexplained by adiposity or standard metabolic parameters. The convergence between this analysis (68.6% unexplained) and the Lancet prespecified analysis (67% weight-independent) from independent methodologies strengthens the anti-inflammatory mechanism hypothesis.
### Auto-enrichment (near-duplicate conversion, similarity=1.00)
*Source: PR #2128 — "semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator"*
*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
### Additional Evidence (confirm)
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
SELECT trial prespecified analysis (N=17,604, published Lancet Nov 2025) confirms ~67% of MACE reduction is independent of weight/adiposity changes. Treatment effect was consistent across ALL baseline BMI and waist circumference categories with no evidence of heterogeneity. Time-varying weight loss analysis showed 'no evidence that the treatment effect of semaglutide was mediated by time-varying weight loss.' Only ~33% of benefit explained by early waist circumference reductions. This is stronger evidence than the ESC 2024 abstract because it's a prespecified (not exploratory) analysis from the definitive SELECT publication.
### Additional Evidence (confirm)
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
ESC 2024 mediation analysis (Colhoun/Lincoff) converges on same conclusion via different methodology: body weight mediates only 19.5% of CV benefit, while hsCRP (inflammation marker) mediates 42.1% - the largest single measured factor. Joint mediation of all measured metabolic/adiposity parameters: 31.4%, leaving ~68.6% pleiotropic/unexplained. The two independent analyses (prespecified SELECT and ESC mediation) both arrive at 67-69% weight-independence through different statistical approaches.
--- ---
### Additional Evidence (confirm) ### Additional Evidence (confirm)